Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease
Recruiting · NCT07203287 · Interventional (participants receive a specific treatment) · Lead sponsor: The University of Texas Medical Branch, Galveston
View the official record on ClinicalTrials.gov →Interventions studied
CisatracuriumNeostigmineRocuroniumSugammadex
What this trial is about
The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is "The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."
Who can take part
Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- The subject is able and willing to provide and sign informed consent
- The subject must be between 18 and 80 years of age
- The subject should have chronic kidney disease as defined by glomerular filtration rate
- The surgery must require general anesthesia with endotracheal intubation and neuromuscular blockade
Exclusion criteria
- Any patient under the age of 18
- Any patient over the age of 80
- Any patient with end stage renal disease
- Any patient requiring dialysis
- Patients presenting for Renal Transplantation
- Pregnant Female
- Any patient in the correctional system
- Urgent or Emergent procedure
- The surgery requires intubation post-operatively
- Documented allergy to Rocuronium, Sugammadex, Cisatracurium or Neostigmine
Where it is running
1 location listed across 1 US state.
- University of Texas Medical Branch - Galveston, Texas, United States